Nemaura Medical (NASDAQ:NMRD) versus Inovio Pharmaceuticals (NASDAQ:INO) Critical Comparison

Nemaura Medical (NASDAQ:NMRD) and Inovio Pharmaceuticals (NASDAQ:INO) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their profitability, valuation, dividends, earnings, risk, analyst recommendations and institutional ownership.

Profitability

This table compares Nemaura Medical and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nemaura Medical	N/A	N/A	N/A
Inovio Pharmaceuticals	N/A	-118.17%	-83.47%

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Nemaura Medical and Inovio Pharmaceuticals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nemaura Medical	0	0	0	0	0.00
Inovio Pharmaceuticals	0	2	3	0	2.60

Inovio Pharmaceuticals has a consensus target price of $12.40, suggesting a potential upside of 466.21%. Given Inovio Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts clearly believe Inovio Pharmaceuticals is more favorable than Nemaura Medical.

Earnings & Valuation

This table compares Nemaura Medical and Inovio Pharmaceuticals”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nemaura Medical	$80,000.00	0.00	-$14.14 million	($0.39)	N/A
Inovio Pharmaceuticals	$203,413.00	281.00	-$135.12 million	N/A	N/A

Nemaura Medical has higher earnings, but lower revenue than Inovio Pharmaceuticals.

Insider & Institutional Ownership

4.4% of Nemaura Medical shares are held by institutional investors. Comparatively, 26.8% of Inovio Pharmaceuticals shares are held by institutional investors. 40.4% of Nemaura Medical shares are held by insiders. Comparatively, 2.5% of Inovio Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Volatility and Risk

Nemaura Medical has a beta of 0.27, indicating that its stock price is 73% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 0.89, indicating that its stock price is 11% less volatile than the S&P 500.

Summary

Inovio Pharmaceuticals beats Nemaura Medical on 6 of the 10 factors compared between the two stocks.

About Nemaura Medical

Nemaura Medical Inc., a medical technology company, manufactures continuous glucose monitoring system in the United States. It offers sugarBEAT, a non-invasive continuous glucose monitoring device for use by persons with Type I and Type II diabetes, as well as screen pre-diabetic patients. The company also offers proBEAT, a wellness guidance notes, that provide prompts and educate users on factors affecting blood sugar profiles, as well as conducts diabetes prevention and reversal programs. Nemaura Medical Inc. was founded in 2009 and is based in New York, New York.

About Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its DNA medicines platform uses precisely designed SynCon that identify and optimize the DNA sequence of the target antigen, as well as CELLECTRA smart devices technology that facilitates delivery of the DNA plasmids. Its products in pipeline include VGX-3100 for the treatment of HPV-related cervical high-grade dysplasia; INO-3107 for HPV-related recurrent respiratory papillomatosis and is under Phase 1/2 trial; INO-3112 for the treatment of HPV-related Oropharyngeal Squamous Cell Carcinoma and is under Phase 2 trial; INO-5401 for the treatment of glioblastoma multiforme and is under Phase 2 trial; INO-4201 for Ebola Virus Disease and is under Phase 1b trial; INO-4800 for COVID-19 and is under Phase 3 trial; and INO-6160 for the treatment of human immunodeficiency virus and is under Phase 1 trial. Its partners and collaborators include Advaccine Biopharmaceuticals Suzhou Co, ApolloBio Corporation, AstraZeneca, The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations, Defense Advanced Research Projects Agency, The U.S. Department of Defense, HIV Vaccines Trial Network, International Vaccine Institute, Kaneka Eurogentec, National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, the Parker Institute for Cancer Immunotherapy, Plumbline Life Sciences, Regeneron Pharmaceuticals, Richter-Helm BioLogics, Thermo Fisher Scientific, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. The company was incorporated in 1983 and is headquartered in Plymouth Meeting, Pennsylvania.